Abstract: The present invention provides a biochip microarray, with multiple properties for use in identification of gene- and protein-induction or repression by drugs, the evaluation of efficacy and toxicity of any drug of choice, prediction of efficacy and toxicity of newly-discovered drugs, families of drugs or classes of drugs. Experimental information acquired from the biochip is inputted into a Drug-Gene-Protein-Biology (DGPB) database from which experimental data can be mined and analyzed based on the users preferences. A method for predicting the effect of a test composition for the treatment of a disease also is described. An animal model for the disease is selected. A biochip array for evaluating the effect of the test composition for the treatment of the disease is provided. The test composition is tested in the animal model to obtain a first set of biological markers representative of the effect of the test composition in the animal model.

Abstract: In accordance with the present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies that bind to CD147 and that result in the killing of such cells, for example, through the binding of complement, is efficacious in the treatment of diseases. Diseases in which such treatment appears efficacious include, without limitation: graft versus host disease (GVHD), organ transplant rejection diseases (including, without limitation, renal transplant, ocular transplant, and others), cancers (including, without limitation, cancers of the blood (i.e., leukemias and lymphomas), pancreatic, and others), autoimmune diseases, inflammatory diseases, and others.

Abstract: In accordance with the present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies that bind to CD147 and that result in the killing of such cells, for example, through the binding of complement, is efficacious in the treatment of diseases. Diseases in which such treatment appears efficacious include, without limitation: graft versus host disease (GVHD), organ transplant rejection diseases (including, without limitation, renal transplant, ocular transplant, and others), cancers (including, without limitation, cancers of the blood (i.e., leukemias and lymphomas), pancreatic, and others), autoimmune diseases, inflammatory diseases, and others.

Abstract: The present invention provides relates to a biochip microarray, with multiple properties for use in identification of gene- and protein-induction or repression by drugs, the evaluation of efficacy and toxicity of any drug of choice, prediction of efficacy and toxicity of newly-discovered drugs, families of drugs or classes of drugs. Experimental information acquired from the biochip is inputted into a Drug-Gene-Protein-Biology (DGPB) database from which experimental data can be mined and analyzed based on the users preferences. A method for predicting the effect of a test composition for the treatment of a disease also is described. An animal model for the diseases selected. A biochip array for evaluating the effect of the test composition for the treatment of the disease is provided. The test composition is tested in the animal model to obtain a first set of biological markers representative of the effect of the test composition in the animal model.

Abstract: A method for modulating an alpha 6 subunit containing integrin-mediated signal transduction is described. The method involves contacting a cell with an effective integrin modulating amount of an alpha 6 subunit containing integrin-mediated signal transduction pathway modification agent. Preferred agents are peptides having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.